Physician profile
Kimo C Stine
NPI 1952491516
$30,915.16
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $9,101 · 2021: $11K · 2022: $10K.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $19,900.61 | 2020-2022 | |
| Bioverativ Therapeutics INC. | $3,546.00 | 2020 | |
| Hema Biologics, LLC | $2,507.84 | 2022 | |
| Genzyme Corporation | $1,839.00 | 2021 | |
| Pfizer INC. | $1,512.06 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $900.00 | 2019 | |
| Janssen Research & Development, LLC | $600.00 | 2021 | |
| Genentech USA, INC. | $109.65 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$7,360.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimo Stine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.